PHYSICOCHEMICAL AND STRUCTURAL-PROPERTIES OF NONSTEROIDAL ANTIINFLAMMATORY OXICAMS

被引:106
作者
TSAI, RS
CARRUPT, PA
ELTAYAR, N
GIROUD, Y
ANDRADE, P
TESTA, B
BREE, F
TILLEMENT, JP
机构
[1] UNIV LAUSANNE,ECOLE PHARM,INST CHIM THERAPEUT,BEP,CH-1015 LAUSANNE,SWITZERLAND
[2] UNIV PARIS 12,FAC MED CRETEIL,PHARMACOL LAB,F-94010 CRETEIL,FRANCE
关键词
D O I
10.1002/hlca.19930760208
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Using the five therapeutic oxicams 1-5, we showed that isosteric replacements result in remarkable changes in the physicochemical and structural properties of congeners. Thus. the acidity of the phenolic OH group is relatively higher in the oxicams containing a pyridinyl moiety, i.e. in piroxicam (1), tenoxicam (2), and lornoxicam (3), due to their zwitterionic nature- This consequently influences their lipophilicity profile at different ionization states. Furthermore, partitioning behaviour in octan-1-ol/H2O and heptane/H2O systems suggests an internal H-bond between the enolic OH and the amide C=O group. The anionic oxicams readily partition into the octanol phase at pH 7.4 and not at all into the heptane phase. Only the partition coefficients of oxicams measured in the heptane/H2O system, but not in the octanol/H2O system, correlate with their transfer across the blood-brain barrier- This implies that only the neutral form of oxicams crosses the blood-brain barrier.
引用
收藏
页码:842 / 854
页数:13
相关论文
共 35 条
[1]  
Albert A., 1984, DETERMINATION IONIZA, P70
[2]   POTENTIOMETRIC DETERMINATION OF DISSOCIATION CONSTANTS [J].
BENET, LZ ;
GOYAN, JE .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1967, 56 (06) :665-&
[3]  
BERNHARD E, 1984, ARZNEIMITTEL-FORSCH, V34-1, P647
[4]   DEUTERIUM-ISOTOPE EFFECTS ON C-13 NMR SHIFTS AND THE TAUTOMERIC EQUILIBRIUM IN N-SUBSTITUTED PYRIDYL DERIVATIVES OF PIROXICAM [J].
BORDNER, J ;
HAMMEN, PD ;
WHIPPLE, EB .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1989, 111 (17) :6572-6578
[5]   BLOOD DISTRIBUTION OF TENOXICAM IN HUMANS - A PARTICULAR HSA DRUG-INTERACTION [J].
BREE, F ;
NGUYEN, P ;
URIEN, S ;
RIANT, P ;
ALBENGRES, E ;
FENNER, H ;
TILLEMENT, JP .
FUNDAMENTAL & CLINICAL PHARMACOLOGY, 1989, 3 (03) :267-279
[6]   A REEVALUATION OF THE HSA-PIROXICAM INTERACTION [J].
BREE, F ;
URIEN, S ;
NGUYEN, P ;
RIANT, P ;
ALBENGRES, E ;
TILLEMENT, JP .
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 1990, 15 (04) :303-307
[7]   PIROXICAM, A POTENT INHIBITOR OF PROSTAGLANDIN PRODUCTION IN CELL-CULTURE - STRUCTURE-ACTIVITY STUDY [J].
CARTY, TJ ;
ESKRA, JD ;
LOMBARDINO, JG ;
HOFFMAN, WW .
PROSTAGLANDINS, 1980, 19 (01) :51-59
[8]  
COHN EJ, 1943, PROTEINS AMINO ACIDS, P96
[9]   DRUG TRANSFER ACROSS THE BLOOD-BRAIN-BARRIER - CORRELATION BETWEEN INVITRO AND INVIVO MODELS [J].
DEHOUCK, MP ;
JOLLIETRIANT, P ;
BREE, F ;
FRUCHART, JC ;
CECCHELLI, R ;
TILLEMENT, JP .
JOURNAL OF NEUROCHEMISTRY, 1992, 58 (05) :1790-1797
[10]   GROUND-STATES OF MOLECULES .39. MNDO RESULTS FOR MOLECULES CONTAINING HYDROGEN, CARBON, NITROGEN, AND OXYGEN [J].
DEWAR, MJS ;
THIEL, W .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1977, 99 (15) :4907-4917